CJC-1295
Also known as: CJC-1295 with DAC, DAC:GRF, Modified GRF with DAC
CJC-1295 (also called CJC-1295 with DAC or DAC:GRF) is a long-acting GHRH analog in the Growth Hormone Secretagogue class. CJC-1295 is a GHRH analog based on GRF(1-29) carrying four amino-acid substitutions that resist dipeptidyl peptidase-4 cleavage, plus a maleimidopropionyl group at the C-terminus.
For research use only.
Key Facts
- CAS
- 446262-90-4
- Molecular Weight (MW)
- 3647.2 g/mol
- Half-life
- ~6–8 days (estimated 5.8–8.1 days in healthy adults after subcutaneous injection)
- FDA status
- Not Approved
- Evidence level
- Limited Human Evidence
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Single and repeated dosing studied; the long-acting DAC form was given at multi-day intervals
- Last updated
- Sep 26, 2026
- Reviewed
- Aug 30, 2026
- Targets
- GHRH receptor
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 24
- Listed offers
- 38
- Median price per mg
- $10.89/mg
- Typical $9.00–$14.00/mg
Research summary
GHRH analog. Catalog “CJC-1295” often means the DAC (Drug Affinity Complex) form that extends half-life via albumin binding. Not FDA-approved. WADA S2 (GHRH analogues).
Peptide Library's CJC-1295 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
CJC-1295 dosage chart
CJC-1295 has been dosed in humans in two published 2006 studies in healthy adults, which gave 30–60 mcg/kg subcutaneously and reported sustained, dose-dependent increases in growth hormone and IGF-1. That is weight-based dosing from small pharmacology studies, not an established therapeutic regimen: the only registered phase 2 trial was terminated, and no product has been approved.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 30–60 mcg/kg subcutaneously (weight-based) |
| Route | Subcutaneous |
| Frequency | Single and repeated dosing studied; the long-acting DAC form was given at multi-day intervals |
| Duration studied | Short pharmacology studies |
| Titration | None reported. Doses were fixed per weight in the published studies. |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Teichman et al., 2006 — healthy adultsClinical trial · Human pharmacology study | Healthy adults | 30 or 60 mcg/kg (doses up to 120 mcg/kg were studied) | Subcutaneous | Single and repeated dosing | Up to 28 days of follow-up | Growth hormone and IGF-1 secretion, safety and tolerability | Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. |
| Continuous GHRH stimulation study, 2006Clinical trial · Human pharmacology study | Healthy adults | Per study protocol | Subcutaneous | — | — | Whether pulsatile GH secretion persists during continuous stimulation | Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. |
| NCT00267527 — phase 2, terminated, no resultsClinical trial · Phase 2 trial, terminated | HIV patients with visceral obesity (n=120 planned) | Not disclosed | Subcutaneous | — | — | Visceral obesity in HIV | NCT00267527 — A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity |
Where sources disagree
- Published human dosing is weight-based (mcg/kg). The fixed 100 mcg or 2 mg doses commonly published elsewhere are not the same thing, and a fixed dose delivers very different exposure across body weights.
- "CJC-1295" is used for two different molecules: the original long-acting form with a Drug Affinity Complex (DAC), which is what the 2006 studies used, and "CJC-1295 no DAC" (also sold as Mod GRF 1-29), which is a different, much shorter-acting peptide. Human dosing data for the DAC form is not evidence for the no-DAC form.
- The only registered clinical trial of CJC-1295 was terminated and posted no results. No product containing it has been approved anywhere.
Reconstitution
Common research vial sizes: 2 mg, 5 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 2 mg | 2 mL | 1 mg/mL | 10 mcg per 0.01 mL |
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- Add 2 mL bacteriostatic water per 2 mg vial.
- Injection Sites
- AbdomenThigh
- Concentration Example
- 2 mg + 2 mL → 1 mg/mL
- Timing Notes
- Evening before bed
- Expected Onset
- 1–2 weeks
How to reconstitute CJC-1295
- Check the vial size and diluent volume. The profile example for CJC-1295 is: Add 2 mL bacteriostatic water per 2 mg vial.
- Swab both vial stoppers and draw the bacteriostatic water into a sterile syringe.
- Add the water slowly down the inside wall of the peptide vial so it does not jet onto the powder, then swirl gently until the solution is clear. Do not shake.
- Record the resulting concentration: 2 mg + 2 mL → 1 mg/mL.
- Label the vial with the date and concentration, refrigerate it (see Storage & stability below), and use the calculator preset to convert a dose in mcg into syringe units.
Sequence & molecular data
| Molecular formula | C165H269N47O46 |
|---|---|
| Molecular weight | 3647.2 g/mol |
| CAS number | 446262-90-4 |
| Half-life | ~6–8 days (estimated 5.8–8.1 days in healthy adults after subcutaneous injection) |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 91971820 |
| FDA UNII | 62RC32V9N7 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
CJC-1295 is a GHRH analog based on GRF(1-29) carrying four amino-acid substitutions that resist dipeptidyl peptidase-4 cleavage, plus a maleimidopropionyl group at the C-terminus. That reactive group forms a covalent bond with cysteine-34 of circulating serum albumin after injection, creating a long-lived depot and extending the half-life from minutes to days. It binds the pituitary GHRH receptor, raising cyclic AMP and stimulating growth hormone synthesis and release, with downstream IGF-1 elevation. Catalogue material sold as CJC-1295 most often means this drug affinity complex form; the term is used inconsistently, and buyers should confirm from the certificate of analysis whether the DAC group is present, since the no-DAC form has a completely different duration of action.
Origin
Stabilized GHRH(1–29) analog; DAC form is albumin-binding.
Targets
Studies
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
Regulatory & research status
CJC-1295 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Research-Only |
Benefits
CJC-1295 side effects
CJC-1295 has only limited human data, so the list below is incomplete and its side-effect profile is not well established.
Side Effects
- Flushing
- Water retention
- Paresthesias
- Injection-site reactions
Contraindications
- Not recommended with diabetes
- Avoid before surgery
Stacking
Common stacking partners
Combinations that include CJC-1295, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
CJC-1295: frequently asked questions
What is CJC-1295?
GHRH analog. Catalog “CJC-1295” often means the DAC (Drug Affinity Complex) form that extends half-life via albumin binding. Not FDA-approved. WADA S2 (GHRH analogues). CJC-1295 is a GHRH analog based on GRF(1-29) carrying four amino-acid substitutions that resist dipeptidyl peptidase-4 cleavage, plus a maleimidopropionyl group at the C-terminus. That reactive group forms a covalent bond with cysteine-34 of circulating serum albumin after injection, creating a long-lived depot and extending the half-life from minutes to days.
What are the side effects of CJC-1295?
CJC-1295 has only limited human data, so its side-effect profile is not well established. Effects recorded on this profile include flushing, water retention, paresthesias and injection-site reactions. Cautions recorded on this profile: not recommended with diabetes and avoid before surgery. It is on the WADA Prohibited List for athletes. This is reference information, not medical advice.
How does CJC-1295 work?
CJC-1295 is a GHRH analog based on GRF(1-29) carrying four amino-acid substitutions that resist dipeptidyl peptidase-4 cleavage, plus a maleimidopropionyl group at the C-terminus. That reactive group forms a covalent bond with cysteine-34 of circulating serum albumin after injection, creating a long-lived depot and extending the half-life from minutes to days.
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of CJC-1295?
CJC-1295 (with DAC) has an estimated half-life of 5.8–8.1 days in healthy adults after subcutaneous injection (Teichman et al., 2006), because it binds covalently to circulating albumin. Half-life describes how long the compound persists in circulation, not how long any effect lasts; the no-DAC form is a different, short-acting molecule.
Is CJC-1295 banned in sport?
CJC-1295 is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to CJC-1295?
Compounds most often compared with CJC-1295 include Sermorelin, Tesamorelin, CJC-1295 (no DAC) / Mod GRF(1-29) and CJC-1295 (no DAC) + Ipamorelin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
How long does CJC-1295 take to show effects in research protocols?
The research protocol on this profile lists an expected onset of 1–2 weeks. This is a protocol note describing when studies and researchers report observing changes, not a measured clinical outcome, and it varies with the model, dose and endpoint studied.
Where is CJC-1295 administered in research protocols?
Research protocols on this profile use subcutaneous administration, with recorded sites including abdomen, thigh. Site rotation and sterile technique are standard practice in the research literature; this describes protocol conditions and is not guidance for use.
References
- WADA Prohibited List 2026External reference
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — J Clin Endocrinol Metab, 2006External reference
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog — J Clin Endocrinol Metab, 2006External reference
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma — Drug Test Anal, 2019External reference
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Front Endocrinol (Lausanne), 2026External reference
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects — Growth Horm IGF Res, 2009External reference
Related research, comparisons & guides
- CJC-1295 and Ipamorelin: Why the Pairing Exists and What the Vial Math Looks Like
- Ipamorelin vs Tesamorelin: Two Receptors, One Approved Drug
- Tesamorelin vs CJC-1295: Same Receptor, Different Clock
- The Wolverine Stack: What It Is and Where the Name Came From
- Ipamorelin
- Sermorelin
- Tesamorelin
- Peptide stacks: combinations by research goalStacks
- Peptide dosage chart: dose, route and frequencyCategory
- Peptide calculator with the CJC-1295 preset
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 26, 2026 · Version 7
This CJC-1295 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track CJC-1295 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →